Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes

Diabetes Care

Volumn 23, Issue 5, 2000, Pages 583-588

  Raskin, Philip ^a,f   Guthrie, Richard A ^b   Leiter, Lawrence ^c   Riis, Anders ^d   Jovanovic, Lois ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Mid America Diabetes Associates PA   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d NOVO NORDISK A S   (Denmark)

^e SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART; INSULIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; TREATMENT INDICATION;

EID: 0034109079     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.5.583     Document Type: Article

References (27)

1. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR: Comparison of subcutaneous soluble human insulin and insulin analogs (AspB9, GluB27, AspB10, AspB28) on meal-related plasma glucose excursions in type 1 diabetic patients. Diabetes Care 14:571-577, 1991
2. Brange J: Design of insulin analogs for meal-related therapy. J Diabetes Complications 7:106-112, 1993
3. Brange J, Owens DR, Kang S, Vølund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13: 923-954, 1990
4. Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR: Comparison of subcutaneous soluble human insulin and insulin analogs (AspB9, GluB27, AspB10, AspB28) on meal-related plasma glucose excursions in type 1 diabetic patients. Diabetes Care 14:571-577, 1991
5. Holleman F, Hoekstra JBL: Insulin lispro. N Engl J Med 337:176-183, 1997
6. Brange J, Vølund A: Insulin analogs with improved pharmacokinetic profiles. Adv Drug Delivery Rev 35:307-335, 1999
7. Heinemann L, Kapitza C, Starke AAR, Heise T: Time-action profile of the insulin analogue B28Asp. Diabet Med 13:683-684, 1996
8. Home PD, Barriocanal L, Lindholm A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analog, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 55:199-203, 1991
9. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry R: Insulin aspart (B28 Asp-Insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 22:1501-1506, 1999
10. Mortensen H, Olsen B, Lindholm A: Pharmacokinetics of a rapid-acting human insulin analogue, insulin aspart, in children and adolescents with type 1 diabetes (Abstract). Diabetes 48:1566, 1999
11. Kang S, Brange J, Burch A, Vølund A, Owens DR: Absorption kinetics and action profiles of subcutaneously administered insulin analogs (Asp89, GluB27, AspB10, AspB28) in healthy subjects. Diabetes Care 14:1057-1065, 1991
12. Kang S, Brange J, Burch A, Vølund A, Owens DR: Subcutaneous insulin absorption explained by insulin's physiochemical properties: evidence from absorption studies of soluble human insulin and insulin analogs in humans. Diabetes Care 14:942-948, 1991
13. Heinemann L, Heise T, Jorgensen LN, Starke AAR: Action profile of the rapid acting insulin analog: human insulin B28Asp. Diabet Med 10:535-539, 1993
14. Wiefels K, Hubinger A, Dannehland K, Gries FA: Insulin kinetic and dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analog (B28 Asp). Horm Metab Res 27:421-424, 1995
15. Heinemann L, Weyer C, Rave K, Stiefelhagen O, Rauhaus M, Heise T: Comparison of the time-action profiles ot U40-and U100-regular human insulin and the rapid-acting insulin analog B28 Asp. Exp Clin Endocrinol Diabetes 105:140-144, 1997
16. Heinemann L, Kapitza C, Starke AAR, Heise T: Time-action profile of the insulin analog B28Asp. Diabet Med 13:683-684, 1996
17. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 21:1904-1909, 1998
18. Bio-Rad Diamat Analyzer System Operations Manual. Hercules, CA, Bio-Rad Laboratories, July 1993
19. lc. Clin Chem 30:1746-1752, 1984
20. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S: Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45:1750-1754, 1996
21. Ottesen J, Nilsson P, Jami J, Weilguny D, Durhrkop M, Bucchini D, Havelund S, Fogh JM: The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178-1185, 1994
22. Andersen JH, Brunelle RL, Kooivisto VA, Trautmann ME, Vignati L, DiMarchi R, and the Multicenter Insulin Lispro Study Group: Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 19:62-71, 1997
23. Jacobs MAJM, Keulen ETP, Kanc K, Casteleijn S, Scheffer P, Deville W, Heine RJ: Metabolic efficacy of preprandial administration of Lys (B28), pro (B29) human insulin analog in IDDM patients. Diabetes Care 20:1279-1286, 1997
24. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart. Diabetes Care 22:801-805, 1999
25. lc in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795-800, 1999
26. Heller SR, Amiel SA, Mansell P: Effect of the fast-acting insulin analog lispro on the risk of noctural hypoglycemia during intensified insulin therapy. Diabetes Care 22:1607-1611, 1999
27. Jansson PA, Ebeling P, Smith U, Conget I, Coves MJ, Gomis R, Lalli C, Del Sindaco P, Bolli GB, Koivisto VA: Improved glycemic control can be better maintained with insulin lispro than with human regular insulin. Diabetes Nutr Metab 11:194-199, 1998